M&A Deal Summary

Roche Acquires Good Therapeutics

On September 7, 2022, Roche acquired life science company Good Therapeutics for 250M USD

Acquisition Highlights
  • This is Roche’s 27th transaction in the Life Science sector.
  • This is Roche’s 18th largest (disclosed) transaction.
  • This is Roche’s 26th transaction in the United States.
  • This is Roche’s 2nd transaction in Washington.

M&A Deal Summary
Date 2022-09-07
Target Good Therapeutics
Sector Life Science
Buyer(s) Roche
Deal Type Add-on Acquisition
Deal Value 250M USD

Target

Good Therapeutics

Seattle, Washington, United States
Good Therapeutics is a biopharmaceutical company focused on the generation of a new class of drugs that offer potent activity only where it is needed. The therapeutic component can be regulated by any molecule that an antibody can bind, including native proteins, modified proteins, and metabolites. Good Therapeutics’ technology is applicable to a wide range of areas including cancer, autoimmune diseases, metabolic disease, and pain management. Good Therapeutics was founded in 2016 and is based in Seattle, Washington.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 40 of 42
Sector (Life Science) 27 of 29
Type (Add-on Acquisition) 35 of 35
State (Washington) 2 of 2
Country (United States) 26 of 28
Year (2022) 1 of 1
Size (of disclosed) 18 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-16 Roche Holding - U.S. Ariosa Centralized Laboratory Prenatal Testing Business

Elmwood Park, New Jersey, United States

Roche Holding's U.S. Ariosa Centralized Laboratory Prenatal Testing Business is a noninvasive prenatal screening (NIPS) test, the Harmony Prenatal Test, which is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million patients. Roche Holding's U.S. Ariosa Centralized Laboratory Prenatal Testing Business is based in Elmwood Park, New Jersey.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-10-23 Telavant

New York, New York, United States

Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.

Buy $7.1B
Mergr

Product

Company

Legal